A team of NCI researchers recently investigated what needs to happen for the United States to reach President Biden’s goal of cutting cancer mortality by 50% by 2047. Read more

During IASLC’s 2023 Hot Topic Meeting on small cell lung cancer, Dr. Trudy Oliver discussed how MYC genes drive the evolution of SCLC subtypes. Read more

From new diagnostic approaches to new evidence on the potential mechanisms of treatment resistance, Dr. Charles M. Rudin looked back on how small cell research has evolved and what needs remain. Read more

The Netherlands Cancer Institute’s Dr. Paul Baas was honored for his significant contributions to lung cancer research during the 2023 European Lung Cancer Congress. Read more

Consensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC. Read more

Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC. Read more

In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field. Read more

Dr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients. Read more

During TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment. Read more

During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more